Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: A brief overview

European Journal of Medicinal Chemistry

Volumn 60, Issue , 2013, Pages 170-186

  Mulakayala, Naveen ^a   Rao, Pallavi ^a   Iqbal, Javed ^a   Bandichhor, Rakeshwar ^b   Oruganti, Srinivas ^a  

^a UNIVERSITY OF HYDERABAD   (India)

^b DR REDDY'S LABORATORIES LTD   (India)

Author keywords

Cladribine; Fingolimod; Laquinimod; Multiple sclerosis; T and B lymphocytes; Teriflunomide

Indexed keywords

ALEMTUZUMAB; ATORVASTATIN; BAF 312; CLADRIBINE; CS 0777; CYCLOPHOSPHAMIDE; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID; LAMOTRIGINE; LAQUINIMOD; MINOCYCLINE; MYCOPHENOLIC ACID; OCRELIZUMAB; RILUZOLE; RITUXIMAB; SIMVASTATIN; TERIFLUNOMIDE; THIOCTIC ACID; TREOSULFAN; UNCLASSIFIED DRUG; ZAURATEGRAST;

ACYLATION; ALLERGIC ENCEPHALOMYELITIS; AMINOLYSIS; AMMONOLYSIS; ANTIINFLAMMATORY ACTIVITY; BIOCATALYSIS; BROMINATION; CHLORINATION; CRYSTALLIZATION; DEACETYLATION; DESULFURIZATION; DIAZOTIZATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; ELIMINATION REACTION; GLYCOSYLATION; HEADACHE; HUMAN; HYDROBORATION; HYDROGENATION; HYDROLYSIS; IMMUNOMODULATION; MICROWAVE IRRADIATION; MULTIPLE SCLEROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; ROOM TEMPERATURE; STEREOSPECIFICITY; SWERN OXIDATION; UPPER RESPIRATORY TRACT INFECTION; WITTIG REACTION;

EID: 84871720707     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.10.055     Document Type: Short Survey

References (163)

1. R. Hohlfeld, and H. Wekerle Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines Proc. Natl. Acad. Sci. U. S. A. 101 Suppl. 2 2004 14599 14606
2. A. Compston, and A. Coles Multiple sclerosis Lancet 372 2008 1502 1517
3. M. Debouverie, S. Pittion-Vouyovitch, S. Louis, F. Guillemin for the LORSEP Group Natural history of multiple sclerosis in a population-based cohort Eur. J. Neurol. 15 2008 916 921
4. P. Sobocki, M. Pugliatti, K. Lauer, and G. Kobelt Estimation of the cost of MS in Europe: extrapolations from a multinational cost study Mult. Scler. 13 8 2007 1054 1064
5. G. Rosati The prevalence of multiple sclerosis in the world: an update Neurol. Sci. 22 2001 117 139
6. Atlas Multiple Sclerosis Resources in the World 2008 2008 WHO Press Geneva p. 56
7. R.W. Motl, Y. Suh, and M. Weikert Symptom cluster and quality of life in multiple sclerosis J. Pain Symptom Manag. 39 2010 1025 1032
8. D. McAlpine Multiple sclerosis: a plea for a fresh outlook Br. Med. J. 1 1957 475 480
9. C.R. Strader, C.J. Pearce, and N.H. Oberlies Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite J. Nat. Prod. 74 2011 900 907
10. S. Sakuma, T. Endo, T. Kanda, H. Nakamura, S. Yamasaki, and T. Yamakawa Synthesis of a novel human PPARδ selective agonist and its stimulatory effect on oligodendrocyte differentiation Bioorg. Med. Chem. Lett. 21 2011 240 244
11. G. Pilz, P. Wipfler, G. Ladurner, and J. Kraus Modern multiple sclerosis treatment-what is approved, what is on the horizon Drug Discov. Today 13 2008 1013 1025
12. P. Wipfler, A. Harrer, G. Pilz, K. Oppermann, E. Trinka, and J. Kraus Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options Drug Discov. Today 16 2011 8 21
13. R.I. Spain, M.H. Cameron, and D. Bourdette Recent developments in multiple sclerosis therapeutics BMC Med. 7 2009 74 79
14. D.H. Miller, and S.M. Leary Primary-progressive multiple sclerosis Lancet Neurol. 10 2007 903 912
15. A. Compston, and A. Coles Multiple sclerosis Lancet 359 2002 1221 1231
16. M. Inglese Multiple sclerosis: new insights and trends AJNR Am. J. Neuroradiol. 27 2006 954 957
17. M. Sospedra, and R. Martin Immunology of multiple sclerosis Annu. Rev. Immunol. 23 2005 683 747
18. S. Stephanie, and S. Nicoline Emerging therapies for multiple sclerosis Int. J. MS Care 12 2010 17 22
19. T. Fujita, K. Inoue, S. Yamamoto, T. Ikumoto, S. Sasaki, R. Toyama, K. Chiba, Y. Hoshino, and T. Okumoto Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite J. Antibiot. 47 1994 208 215
20. T. Fujimoto, S. Sakoda, H. Fujimura, and T. Yanagihara Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in dark august rats J. Neuroimmunol. 95 1999 35 42
21. L. Kappos, J. Antel, G. Comi, X. Montalban, P. O'Connor, C.H. Polman, T. Haas, A.A. Korn, G. Karlsson, E.W. Radue for the FTY720 D2201 study group Oral fingolimod (FTY720) for relapsing multiple sclerosis N. Engl. J. Med. 355 2006 1124 1140
22. V. Brinkmann FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system Br. J. Pharmacol. 158 2009 1173 1182
23. G.M.L. Meno-Tetang, H. Li, S. Mis, N. Pyszczynski, P. Heining, P. Lowe, and W.J. Jusko Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses Drug Metab. Dispos. 34 2006 1480 1487
24. S.S. Chae, R.L. Proia, and T. Hla Constitutive expression of the S1P1 receptor in adult tissues Prostaglandins Other Lipid Mediat. 73 2004 141 150
25. C.A. Foster, L.M. Howard, A. Schweitzer, E. Persohn, P.C. Hiestand, B. Balatoni, R. Reuschel, C. Beerli, M. Schwartz, and A. Billich Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis J. Pharmacol. Exp. Ther. 323 2007 469 476
26. J.A. Cohen, F. Barkhof, G. Comi, H.-P. Hartung, B.O. Khatri, X. Montalban, J. Pelletier, R. Capra, P. Gallo, G. Izquierdo, K. Tiel-wilck, A. de Vera, J. Jin, T. Stites, S. Wu, S. Aradhye, L. Kappos for the TRANSFORMS Study Group Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N. Engl. J. Med. 362 2010 402 415
27. J.H. Noseworthy, J.S. Wolinsky, F.D. Lublin, J.N. Whitaker, A. Linde, P. Gjorstrup, H.C. Sullivan the north american linomide investigators Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results Neurology 54 2000 1726 1733
28. G. Comi, A. Pulizzi, M. Rovaris, O. Abramsky, T. Arbizu, A. Boiko, R. Gold, E. Havrdova, S. Komoly, K.W. Selmaj, B. Sharrack, M. Filippi for the LAQ/5062 study group Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, placebo-controlled phase IIb study Lancet 371 2008 2085 2092
29. C. Polman, F. Barkhof, M. Sandberg-Wollheim, A. Linde, O. Nordle, T. Nederman for the Laquinimod in Relapsing MS Study Group Treatment with laquinimod reduces development of active MRI lesions in relapsing MS Neurology 64 2005 987 991
30. J. Preiningerova Oral laquinimod therapy in relapsing multiple sclerosis Expert Opin. Investig. Drugs 18 2009 985 989
31. A. Tselis Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis Curr. Opin. Investig. Drugs 11 2010 577 585
32. T.P. Leist, and P. Vermersch The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation Curr. Med. Res. Opin. 23 2007 2667 2676
33. G. Juliusson, I. Christiansen, M.M. Hansen, S. Johnson, E. Kimby, A. Elmhorn-Rosenborg, and J. Liliemark Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia J. Clin. Oncol. 14 1996 2160 2166
34. E. Beutler, J.C. Sipe, J.S. Romine, J.A. Koziol, R. McMillan, and J. Zyroff The treatment of chronic progressive multiple sclerosis with cladribine Proc. Natl. Acad. Sci. U. S. A. 93 1996 1716 1720
35. G.P.A. Rice, M. Filippi, G. Comi for the cladribine clinical study group and for the cladribine MRI study group Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial Neurology 54 2000 1145 1155
36. J.S. Romine, J.C. Sipe, J.A. Koziol, J. Zyroff, and E. Beutler A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis Proc. Assoc. Am. Physicians 111 1999 35 44
37. J.A. Brousil, R.J. Roberts, and A.L. Schlein Cladribine: an investigational immunomodulatory agent for multiple sclerosis Ann. Pharmacother. 40 2006 1814 1821
38. T. Korn, T. Magnus, K. Toyka, and S. Jung Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide-mechanisms independent of pyrimidine depletion J. Leukoc. Biol. 76 2004 950 960
39. P.W. O'Connor, D. Li, M.S. Freedman, A. Bar-Or, G.P.A. Rice, C. Confavreux, D.W. Paty, J.A. Stewart, and R. Scheyer A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses Neurology 66 2006 894 900
40. H. Lassmann, and R.M. Ransohoff The CD4-Th1 model for multiple sclerosis: a crucial re-appraisal Trends Immunol. 25 2004 132 137
41. H.F. McFarland, and R. Martin Multiple sclerosis: a complicated picture of autoimmunity Nat. Immunol. 8 2007 913 919
42. T. Holmoy, and A.L. Hestvik Multiple sclerosis: immunopathogenesis and controversies in defining the cause Curr. Opin. Infect. Dis. 21 2008 271 278
43. J.H. Noseworthy, C. Lucchinetti, M. Rodriquez, and B.G. Weinshenker Multiple sclerosis N. Engl. J. Med. 343 2000 938 952
44. F.D. Lublin, S.C. Reingold National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis Defining the clinical course of multiple sclerosis: results of an international survey Neurology 46 1996 907 911
45. B.G. Weinshenker, B. Bass, G.P.A. Rice, J. Noseworthy, W. Carriere, J. Baskerville, and G.C. Ebers The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability Brain 112 1989 133 146
46. E.M. Frohman, M.K. Racke, and C.S. Raine Multiple sclerosis-the plaque and its pathogenesis N. Engl. J. Med. 354 2006 942 955
47. L.K. Peterson, and R.S. Fujinami Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis J. Neuroimmunol. 184 2007 37 44
48. C. Lucchinetti, W. Brück, J. Parisi, B. Scheithauer, M. Rodriguez, and H. Lassmann Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination Ann. Neurol. 47 2000 707 717
49. C.H. Polman, S.C.Reingold, G. Edan, M. Filippi, H.-P. Hartung, L. Kappos, F.D. Lublin, L.M. Metz, H.F. Mcfarland, P.W. O'Connor, M. Sandberg-Wollheim, A.J. Thompson, B.G. Weinshenker, and J.S. Wolinsky Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria" Ann. Neurol. 58 2005 840 846
50. D.A. Hafler Multiple sclerosis J. Clin. Invest. 113 2004 788 794
51. C. Confavreux, S. Vukusic, T. Moreau, and P. Adeleine Relapses and progression of disability in multiple sclerosis N. Engl. J. Med. 343 2000 1430 1438
52. D.S. Goodin, E.M. Frohman, G.P. Garmany Jr., J. Halper, W.H. Likosky, F.D. Lublin, D.H. Silberberg, W.H. Stuart, and S. van den Noort Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the american academy of neurology and the MS council for clinical practice guidelines Neurology 58 2002 169 178
53. S.A. Rizvi, and M.A. Aqius Current approved options for treating patients with multiple sclerosis Neurology 63 2004 8 14
54. A. Boster, G. Edan, E. Frohman, A. Javed, O. Stuve, A. Tselis, H. Weiner, B. Weinstock-Guttman, and O. Khan Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician Lancet Neurol. 7 2008 173 183
55. L. Kappos, C.H. Polman, M.S. Freedman, G. Edan, H.P. Hartung, D.H. Miller, X. Montalban, F. Barkhof, L. Bauer, P. Jakobs, C. Pohl, R. Sandbrink for the BENEFIT study group Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurology 67 2006 1242 1249
56. G. Comi, M. Filippi, F. Barkhof, L. Durelli, G. Edan, O. Fernández, H.-P. Hartung, P. Seeldrayers, P.S. Sørensen, M. Rovaris, V. Martinelli, O.R. Hommes the early treatment of multiple sclerosis study group Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study Lancet 357 2001 1576 1582
57. L.D. Jacobs, R.W. Beck, J.H. Simon, R.P. Kinkel, C.M. Brownscheidle, T.J. Murray, N.A. Simonian, P.J. Slasor, A.W. Sandrock the CHAMPS Study Group Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis N. Engl. J. Med. 343 2000 898 904
58. E. Waubant, S. Vukusic, L. Gignoux, F. Durand-Dubief, I. Achiti, S. Blanc, C. Renoux, and C. Confavreux Clinical characteristics of responders to interferon therapy for relapsing MS Neurology 61 2003 184 189
59. M. Filippi, J.S. Wolinsky, G. Comi the CORAL study group Effects of oral glatiramer acetate on clinical and MRI monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study Lancet Neurol. 5 2006 213 220
60. J.S. Wolinsky, P.A. Narayana, P. O'Connor, P.K. Coyle, C. Ford, K. Johnson, A. Miller, L. Pardo, S. Kadosh, D. Ladkani the PROMiSe trial study group Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial Ann. Neurol. 61 2007 14 24
61. A.M. Vallittu, J. Peltoniemi, I. Elovaara, H. Kuusisto, M. Färkkilä, J. Multanen, and J.P. Eralinna The efficacy of glatiramer acetate in β-interferon-intolerant MS patients Acta Neurol. Scand. 112 2005 234 237
62. A. Miller, V. Spada, D. Beerkircher, and R.R. Kreitman Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing remitting multiple sclerosis Mult. Scler. 14 2008 494 499
63. J. Ramtahal, A. Jacob, K. Das, and M. Boggild Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis J. Neurol. 253 2006 1160 1164
64. A.J. Coles, E. Fox, A. Vladic, S.K. Gazda, V. Brinar, K.W. Selmaj, A.D. Bass, D.R. Wynn, D.H. Margolin, S.L. Lake, S. Moran, J. Palmer, M.S. Smith, and D.A. Compston Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes Lancet Neurol. 10 2011 338 348
65. O. Khan on behalf of the CAMMS223 Study Group Alemtuzumab reduces disease progression in RRMS: long-term results of the CAMMS323 trial Neurology 74 Suppl. 2 2010 A371 Abstract PO4.213
66. C.H. Polman, P.W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D.H. Miller, J.T. Phillips, F.D. Lublin, G. Giovannoni, A. Wajgt, M. Toal, F. Lynn, M.A. Panzara, A.W. Sandrock for the AFFIRM investigators A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N. Engl. J. Med. 354 2006 899 910
67. D.H. Miller, O.A. Khan, W.A. Sheremata, L.D. Blumhardt, G.P.A. Rice, M.A. Libonati, A.J. Willmer-Hulme, C.M. Dalton, K.A. Miszkiel, P.W. O'Connor for the international natalizumab multiple sclerosis trial group A controlled trial of natalizumab for relapsing multiple sclerosis N. Engl. J. Med. 348 2003 15 23
68. C.P. Kamm, H.P. Mattle SWABIMS study group Swiss atorvastatin and interferon beta-1b trial in multiple sclerosis (SWABIMS)-rationale, design and methodology Trials 10 2009 115 121
69. F. Paul, S. Waiczies, J. Wuerfel, J. Bellmann-Strobl, J. Dörr, H. Waiczies, M. Haertle, K.D. Wernecke, H.-D. Volk, O. Aktas, and F. Zipp Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis PLoS One 3 2008 e1928
70. E. Krasulová, M. Trněný, T. Kozák, B. Vacková, D. Pohlreich, D. Kemlink, P. Kobylka, I. Kovárová, P. Lhotáková, and E. Havrdová High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience Mult. Scler. 16 2010 685 693
71. L. Rinaldi, P. Perini, M. Calabrese, and P. Gallo Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks Neurol. Sci. 30 2009 171 173
72. R.J. Schwartzman, N. Simpkins, G.M. Alexander, E. Reichenberger, K. Ward, N. Lindenberg, D. Topolsky, and P. Crilley High-dose cyclophosphamide in the treatment of multiple sclerosis CNS Neurosci. Ther. 15 2009 118 127
73. L. Kappos, R. Gold, D.H. Miller, D.G. Macmanus, E. Havrdova, V. Limmroth, C.H. Polman, K. Schmierer, T.A. Yousry, M. Yang, M. Eraksoy, E. Meluzinova, I. Rektor, K.T. Dawson, A.W. Sandrock, G.N. O'Neill for the BG-12 Phase IIb study investigators Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study Lancet 372 2008 1463 1472
74. L.M. Metz, D. Li, A. Traboulsee, M.L. Myles, P. Duquette, J. Godin, M. Constantin, V.W. Yong for the GA/minocycline study investigators Glatiramer acetate in combination with minocycline in patients with relapsing-remitting multiple sclerosis: results of a canadian, multicenter, double-blind, placebo-controlled trial Mult. Scler. 15 10 2009 1183 1194
75. ®) in multiple sclerosis Eur. J. Neurol. 14 2007 85 89
76. M. Togha, S.A. Karvigh, M. Nabavi, N.B. Moghadam, M.H. Harirchian, M.A. Sahraian, A. Enzevaei, A. Nourian, H. Ghanaati, K. Firouznia, A. Jannati, and M. Shekiba Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial Mult. Scler. 16 7 2010 848 854
77. H. Wiendl, B.C. Kieseier, R. Weissert, H.A. Mylius, U. Pichlmeier, H.P. Hartung, A. Melms, W. Kuker, and M. Weller Treatment of active secondary progressive multiple sclerosis with treosulfan J. Neurol. 254 2007 884 889
78. J.W. Rose, J.B. Burns, J. Bjorklund, J. Klein, H.E. Watt, and N.G. Carlson Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results Neurology 69 2007 785 789
79. D. Wynn, M. Kaufman, X. Montalban, T. Vollmer, J. Simon, J. Elkins, G. O'Neill, L. Neyer, J. Sheridan, C. Wang, A. Fong, and J.W. Rose Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta Lancet Neurol. 9 2010 381 390
80. M. Buttmann Treating multiple sclerosis with monoclonal antibodies: a 2010 update Expert Rev. Neurother. 10 2010 791 809
81. S.L. Hauser, E. Waubant, D.L. Arnold, T. Vollmer, J. Antel, R.J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal, A. Langer-Gould, and C.H. Smith B-cell depletion with rituximab in relapsing-remitting multiple sclerosis N. Engl. J. Med. 358 2008 676 688
82. K. Hawker, P. O'Connor, M.S. Freedman, P.A. Calabresi, J. Antel, J. Simon, S. Hauser, E. Waubant, T. Vollmer, H. Panitch, J. Zhang, P. Chin, and C.H. Smith Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial Ann. Neurol. 66 2009 460 471
83. P. Gergely, B. Nuesslein-Hildesheim, D. Guerini, V. Brinkmann, M. Traebert, C. Bruns, S. Pan, N.S. Gray, K. Hinterding, N.G. Cooke, A. Groenewegen, A. Vitaliti, T. Sing, O. Luttringer, J. Yang, A. Gardin, N. Wang, W.J. Crumb Jr., M. Saltzman, M. Rosenberg, and E. Wallström The selective S1P receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate: translation from preclinical to clinical studies Br. J. Pharmacol. 2012 10.1111/j.1476-5381.2012.02061.x
84. C. Polman, J. Bowen, F. Barkhof, D. Bates, D. Wynn, C. Wolf, T. Morris, P. Duda, B. Weinkauf, F. Lynn, and B. Bennett Double-blind, placebo-controlled randomized phase II serial MRI, safety and tolerability study of two doses of CDP323 in subjects with relapsing forms of multiple sclerosis over 24 weeks Neurology 74 2010 A293
85. J.B. Moberly, D.M. Ford, H. Zahir, S. Chen, T. Mochizuki, K.E. Truitt, and T.L. Vollmer Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients J. Neuroimmunol. 246 2012 100 107
86. 1 agonist Med. Chem. Lett. 2 5 2011 368 372
87. R. Kapoor, J. Furby, T. Hayton, K.J. Smith, D.R. Altmann, R. Brenner, J. Chataway, R.A.C. Hughes, and D.H. Miller Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial Lancet Neurol. 9 2010 681 688
88. F.J. Rivera, S. Couillard-Despres, X. Pedre, S. Ploetz, M. Caioni, C. Lois, U. Bogdahn, and L. Aigner Mesenchymal stem cells instruct oligodendrogenic fate decision on adult neural stem cells Stem Cells 24 2006 2209 2219
89. V. Yadav, G. Marracci, J. Lovera, W. Woodward, K. Bogardus, W. Marquardt, L. Shinto, C. Morris, and D. Bourdette Lipoic acid in multiple sclerosis: a pilot study Mult. Scler. 11 2005 159 165
90. J. Killestein, N.F. Kalkers, and C.H. Polman Glutamate inhibition in MS: the neuroprotective properties of riluzole J. Neurol. Sci. 233 2005 113 115
91. S.W. Paugh, S.G. Payne, S.E. Barbour, S. Milstien, and S. Spiegel The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2 FEBS Lett. 554 2003 189 193
92. A. Billich, F. Bornancin, P. Dévay, D. Mechtcheriakova, N. Urtz, and T. Baumruker Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases J. Biol. Chem. 278 2003 47408 47415
93. T. Sanchez, T. Estrada-Hernandez, J.H. Paik, M.T. Wu, K. Venkataraman, V. Brinkmann, K. Claffey, and T. Hla Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability J. Biol. Chem. 278 2003 47281 47290
94. T. Fujita, M. Yoneta, R. Hirose, S. Sasaki, K. Inoue, M. Kiuchi, S. Hirase, K. Adachi, M. Arita, and K. Chiba Simple compounds, 2-alkyl-2-amino-1,3- propane diols have potent immunosuppressive activity Bioorg. Med. Chem. Lett. 5 1995 847 852
95. K. Adachi, T. Kohara, N. Nakao, M. Arita, K. Chiba, T. Mishina, S. Sasaki, and T. Fujita Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: discovery of a novel immunosuppressant, FTY720 Bioorg. Med. Chem. Lett. 5 1995 853 856
96. M. Kiuchi, K. Adachi, T. Kohara, M. Minoguchi, T. Hanano, Y. Aoki, T. Mishina, M. Arita, N. Nakao, M. Ohtsuki, Y. Hoshino, K. Teshima, K. Chiba, S. Sasaki, and T. Fujita Synthesis and immunosuppressive activity of 2-Substituted 2-aminopropane-1,3-diols and 2- aminoethanols J. Med. Chem. 43 2000 2946 2961
97. G. Seidel, D. Laurich, and A. Fürstner Iron-catalyzed cross-coupling reactions. A scalable synthesis of the immunosuppressive agent FTY720 J. Org. Chem. 69 2004 3950 3952
98. G.W. Breton Selective monoacetylation of unsymmetrical diols catalyzed by silica gel-supported sodium hydrogen sulfate J. Org. Chem. 62 1997 8952 8954
99. P. Durand, P. Peralba, F. Sierra, and P. Renaut A new efficient synthesis of the immunosuppressive agent FTY-720 Synthesis 2000 505 506
100. 2 system: a short synthesis of immunosuppressive agent FTY-720 Synlett 9 2001 1411 1414
101. K. Hinterding, S. Cottens, R. Albert, F. Zecri, P. Buehlmayer, C. Spanka, V. Brinkmann, P. Nussbaumer, P. Ettmayer, K. Hoegenauer, N. Gray, and S. Pan Synthesis of chiral analogues of FTY720 and its phosphate Synthesis 11 2003 1667 1670
102. F. Tetsuro, S. Shigeo, Y. Masahiko, M.T. Yoshitomi Phar, A.K. Yoshitomi Phar, and C.K. Yoshitomi Pharmac 2-Amino-1,3-propanediol Compound and Immunosuppressant EP 0627406 1994
103. M. Tadashi, O. Toshiyuki, and A. Kunitomo Novel Process for Producing 2-amino-2-(2-(4-octylphenyl)ethyl) Propane-1,3-diol, JP11310556 1999
104. D. Yin, D. Wang, and Y. Zhang Method for Preparing 2-[2-(4-alkylphenyl)- ethyl]-2-amino-propanediol and Intermediates Useful in Such Preparation, WO/2000/053569 2000
105. T.J. Barton, and B.L. Groh Gas-phase thermal rearrangements of potential vinylidene precursors to silylbenzofurans and silylbenzopyrans J. Org. Chem. 50 1985 158 166
106. H.C. Brown, and S.K. Gupta Hydroboration. XXXIX. 1,3,2-benzodioxaborole (catecholborane) as a new hydroboration reagent for alkenes and alkynes. A general synthesis of alkane- and alkeneboronic acids and esters via hydroboration. Directive effects in the hydroboration of alkenes and alkynes with catecholborane J. Am. Chem. Soc. 97 1975 5249 5255
107. H.C. Brown, and S.K. Gupta Catecholborane (1,3,2-benzodioxaborole) as a new, general monohydroboration reagent for alkynes. A convenient synthesis of alkeneboronic esters and acids from alkynes via hydroboration J. Am. Chem. Soc. 94 1972 4370 4371
108. S. Sugiyama, S. Arai, M. Kiriyama, and K. Ishii A convenient synthesis of immunosuppressive agent FTY720 using the petasis reaction Chem. Pharm. Bull. 53 1 2005 100 102
109. H. Ooi, N. Ishibashi, Y. Iwabuchi, J. Ishihara, and S. Hatakeyama A concise route to (+)-lactacystin J. Org. Chem. 69 2004 7765 7768
110. J.W. Lane, and R.L. Halcomb New design concepts for constraining glycosylated amino acids Tetrahedron 57 2001 6531
111. G.J. Roth, B. Liepold, S.G. Müller, and H.J. Bestmann Further improvements of the synthesis of alkynes from aldehydes Synthesis 2004 59 62
112. T. Abe, T. Yamaji, and T. Kitamura synthesis, solubility, and reaction of long alkyl-chained hypervalent iodine benzyne precursors Bull. Chem. Soc. Jpn. 76 2003 2175 2178
113. K. Sonogashira E. Negishi, Handbook of Organopalladium Chemistry for Organic Synthesis 2002 Wiley New York 493
114. S. Kim, H. Lee, M. Lee, and T. Lee Efficient synthesis of the immunosuppressive agent FTY720 Synthesis 2006 753 755
115. N. Matsumoto, R. Hirose, S. Sasaki, and T. Fujita Synthesis of the key intermediate, diethyl 2-acetylamino-2-(2-(4-octanoylphenyl)ethyl)propane-1,3- dioate, of the immunomodulatory agent FTY720 (Fingolimod) Chem. Pharm. Bull. 56 4 2008 595 597
116. v; III: construction of the protected hexapeptide and deprotection Synthesis 1993 815 818
117. A. Scattergood, and A.L. MacLean Some cyclic acetals of tris-(hydroxymethyl)-nitromethane and their derivatives J. Am. Chem. Soc. 71 1949 4153 4154
118. R.Y.Y. Ko, J.C.K. Chu, and P. Chiu Synthesis of fluorinated analogues of the immunosuppressive drug FTY720 Tetrahedron 67 2011 2542 2547
119. J. McNulty, P. Das, and D. McLeod Microwave-assisted, aqueous wittig reactions: organic-solvent- and protecting-group-free chemoselective synthesis of functionalized alkenes Chem. Eur. J. 16 2010 6756 6760
120. J. McNulty, and P. Das Highly stereoselective and general synthesis of (E)-stilbenes and alkenes by means of an aqueous wittig reaction Eur. J. Org. Chem. 24 2009 4031 4035
121. J. Calzavara, and J. McNulty A convergent synthesis of the immunosuppressant FTY720 employing aqueous wittig chemistry Tetrahedron Lett. 52 2011 5672 5675
122. J.-S. Yang, L.-Y. Xu, B.-G. Xiao, G. Hedlund, and H. Link Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats J. Neuroimmunol. 156 2004 3 9
123. O. Andersen, J. Lycke, P.O. Tollesson, A. Svenningsson, B. Runmarker, A.S. Linde, M. Astrom, P. Gjorstrup, and S. Ekholm Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis Neurology 47 1996 895 900
124. G.M. Coppola The chemistry of isatoic anhydride Synthesis 1980 505 536
125. G.M. Coppola, G.E. Hardtmann, and O.R. Pfister Chemistry of 2H-3,1-benzoxazine-2,4(1H)dione (isatoic anhydride). 2. Reactions with thiopseudoureas and carbanions J. Org. Chem. 41 1976 825 831
126. A. Björk, S. Jönsson, T. Fex, and G. Hedlund Quinoline Derivatives, US 6,077,851 2000
127. R.A.W. Johnstone, D.W. Payling, and C.A. Thomas Rapid method of N-alkylating of amines J. Chem. Soc. 1969 2223 2224
128. S. Jönsson, G. Andersson, T. Fex, T. Fristedt, G. Hedlund, K. Jansson, L. Abramo, I. Fritzson, O. Pekarski, A. Runström, H. Sandin, I. Thuvesson, and A. Björk Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: Structure-activity relationship J. Med. Chem. 47 2004 2075 2088
129. K. Jansson, T. Fristedt, A. Olsson, B. Svensson, and S. Jönsson Synthesis and reactivity of laquinimod, a quinoline-3-carboxamide: intramolecular transfer of the enol proton to a nitrogen atom as a plausible mechanism for ketene formation J. Org. Chem. 71 2006 1658 1667
130. K. Jansson Process for the Manufacture of Quinoline Derivatives, US 2004/0034227 A1 2004
131. K. Jansson Process for the Manufacture of Quinoline Derivatives, US 2005/0215586 A1 2005
132. J. Karl Process for the Manufacture of Quinoline Derivatives, WO 2003/106424 A1 2003
133. K. Jansson Process for the Manufacture of Quinoline Derivatives, US 6,875,869 B2 2005
134. J. Wennerberg, A. Björk, T. Fristedt, B. Granquist, K. Jansson, and I. Thuvesson Development of a practical and reliable synthesis of laquinimod Org. Process. Res. Dev. 11 2007 674 680
135. G.T. Gant, and M.M. Shahbaz 2-Oxo-1,2-dihydro-quinoline Modulators of Immune Function, US 2010/0055072 A1 2010
136. H. Venner Synthesis of the corresponding 2-deoxy-nucleosides of adenine, guanine and hypoxanthine Chem. Ber. 93 1 1960 140 149
137. M. Ikehara, and H. Tada Studies of nucleosides and nucleotides. XXIV. Purine cyclonucleosides. I. 8,2′-cyclonucleoside derived from 2-chloro-8-mercapto-9-β-D-xylofuranosyladenine J. Am. Chem. Soc. 87 3 1965 606 610
138. M.J. Robins, and R.K. Robins Purine nucleosides. XI. The synthesis of 2′-deoxy-9-α- and -β-D-ribofuranosylpurines and the correlation of their anomeric structure with proton magnetic resonance spectra J. Am. Chem. Soc. 87 1965 4934 4940
139. L.F. Christensen, A.D. Broom, M.J. Robins, and A. Bloch Synthesis and biological activity of selected 2,6-disubstituted-(2-deoxy-α-and-β-D- erythro-pentofuranosyl)purines J. Med. Chem. 15 1972 735 739
140. Z. Kazimierczuk, H.B. Cottam, G.R. Revankar, and R.K. Robins Synthesis of 2′-deoxytubercidin, 2′-deoxyadenosine, and related 2′-deoxynucleosides via a novel direct stereospecific sodium salt glycosylation procedure J. Am. Chem. Soc. 106 1984 6379 6382
141. M.J. Robins, and B. Uznański Nucleic acid related compounds. 33. Conversions of adenosine and guanosine to 2,6-dichloro, 2-amino-6-chloro, and derived purine nucleosides Can. J. Chem. 59 1981 2601 2607
142. R.H.K. Chen Intermediates Useful in a Synthesis of 2-chloro-2′- deoxyadenosine, US 5208327 1988
143. S. Gerszberg, and D. Alonso Method for the Production of 2-Chloro-2′-Deoxyadenosine (Cladribine) and its 3,5-Di-O-p-Toluoyl Derivative, WO 2000064918 2000
144. I.A. Mikhailopulo, A.I. Zinchenko, Z. Kazimierczuk, V.N. Barai, S.B. Bokut, and E.N. Kalinichenko Synthesis of 2-chloro-2′-deoxyadenosine by microbiological transglycosylation Nucleosides & Nucleotides 12 1993 417 422
145. V.N. Barai, A.I. Zinchenko, L.A. Eroshevskaya, E.N. Kalinichenko, T.I. Kulak, and I.A. Mikhailopulo A universal biocatalyst for the preparation of base- and sugar-modified nucleosides via an enzymatic transglycosylation Helv. Chim. Acta 85 7 2002 1901 1908
146. A. Matsuda, M. Shinozaki, M. Suzuki, K. Watanabe, and T. Miyasaka A convenient method for the selective acylation of guanine nucleosides Synthesis 1986 385 386
147. 6 position by mitomycin C Tetrahedron Lett. 29 1988 4673 4676
148. Z. Janeba, P. Francom, and M.J. Robins Efficient syntheses of 2-chloro-2′-deoxyadenosine (Cladribine) from 2′-deoxyguanosine J. Org. Chem. 68 2003 989 992
149. P.K. Gupta, and S.A. Munk Process for the Preparation of 9-beta-anomeric Nucleoside Analogs, US 20040039190 2005
150. M. Zhong, I. Nowak, and M.J. Robins Regiospecific and highly stereoselective coupling of 6-(substituted-imidazol-1-yl)purines with 2-deoxy-3,5-di-O-(p-toluoyl)-α-d-erythro-pentofuranosyl chloride. Sodium-salt glycosylation in binary solvent mixtures: improved synthesis of cladribine J. Org. Chem. 71 2006 7773 7779
151. J.P. Henschke, X. Zhang, G. Chu, L. Mei, and Y. Chen Process for the Preparation of Cladribine, WO 2011/020298 A1 2011
152. M.J. Robins, J.S. Wilson, L. Sawyer, and M.N.G. James Nucleic acid related compounds. 41. Restricted furanose conformations of 3′,5′-O- (1,1,3,3-tetraisopropyldisilox-1,3-diyl)nucleosides provide a convenient evaluation of anomeric configuration Can. J. Chem. 61 8 1983 1911 1920
153. S. Xu, P. Yao, G. Chen, and H. Wang A new synthesis of 2-chloro-2′-deoxyadenosine (Cladribine), CdA Nucleosides, Nucleotides and Nucleic Acids 30 2011 353 359
154. D. Magne, F. Mézin, G. Palmer, and P.-A. Guerne The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1â and TNF-α Inflamm. Res. 55 2006 469 475
155. R.R. Bartlett, and F.-J. Kämmerer Isoxazole-4-carboxamides and Hydroxyalkylidenecyano Acetamides, Pharmaceuticals Containing These Compounds and Their Use, US 5494911 1996
156. R.R. Bartlett, K.U. Weithmann, and E.S. Kurtz Pharmaceutical for the Treatment of Skin Disorders, US 5504084 1996
157. E.A. Kuo, P.T. Hambleton, D.P. Kay, P.L. Evans, S.S. Matharu, E. Little, N. McDowall, C. Beth Jones, C.J.R. Hedgecock, C.M. Yea, A.W. Edith Chan, P.W. Hairsine, I.R. Ager, W. Roger Tully, R.A. Williamson, and R. Westwood Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N- [3′-methyl-4′-(trifluoromethyl)phenyl]propenamide and related compounds J. Med. Chem. 39 1996 4608 4621
158. F.M. Uckun, Y. Zheng, and S. Ghosh Inhibitors of the EGF-receptor Tyrosine Kinase and Methods for Their Use, US 6355678 2002
159. S. Mahajan, S. Ghosh, E.A. Sudbeck, Y. Zheng, S. Downs, M. Hupke, and F.M. Uckun Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 [α-cyano-β-hydroxy- β-methyl-N-(2,5-dibromophenyl)propenamide] J. Biol. Chem. 274 1999 9587 9599
160. G. Triola, S. Wetzel, B. Ellinger, M.A. Koch, K. Hübel, D. Rauh, and H. Waldmann ATP competitive inhibitors of d-alanine-d-alanine ligase based on protein kinase inhibitor scaffolds Bioorg. Med. Chem. 17 2009 1079 1087
161. D. Keshav, P. Samir, D. Snehal, S. Sunil, and R. Vishal A Process for the Preparation of Teriflunomide, WO 2009/147624 A2 2009
162. D. Keshav, P. Samir, D. Snehal, S. Sunil, and R. Vishal A Process for Preparing Teriflunomide, WO 2010/013159 A1 2010
163. J. Hachtel, B. Neises, W. Schwab, R. Utz, and M. Zahn Process for Preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides, US 2004/0186173 A1 2004